The study was performed in 35 UK hospitals and evaluated the results of 3 multigene tests (Oncotype DX, MammaPrint and Prosigna) on patients > 40 years with HR+/HER2- early breast cancer and node involvement (1 to 9) or, alternatively, tumour size > 3 cm and N0. Here, ERBB2 is linked to breast cancer.